July 24, 2023 11:09 AM EDT
R&D

As Am­gen ac­qui­si­tion faces on­go­ing suit, Hori­zon's mid-stage lu­pus tri­al fails

Lei Lei Wu

News Reporter

Hori­zon Ther­a­peu­tics dis­closed Fri­day af­ter­noon that its an­ti­body drug daxdil­imab failed a mid-stage study for lu­pus.

In the 214-pa­tient Phase II …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Benev­o­len­tAI’s co-founder is back. Here’s how he plans a turn­around at the AI com­pa­ny dur­ing a ‘piv­otal time’

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

GSK leaves biotech trade group BIO

Ei­sai slash­es Leqem­bi sales fore­cast by al­most $100M

New Trump era could be a boon for bio­phar­ma M&A, deal­mak­ing

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times